ClinicalTrials.gg
RecruitingNCT07151729Updated Sep 3, 2025

Use of Anodal tDCS to Enhance Upper Limb Recovery in Stroke

An interventional study of Anodal tDCS and Sham tDCS in Stroke, sponsored by Tan Tock Seng Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Tan Tock Seng Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Stroke by Tan Tock Seng Hospital — 3 open to participants now, 6 under way, none of them phase 3. Stroke · Tan Tock Seng Hospital.

Planned enrollment
2nd of 20
50 · median 17
Started
2025
with 2 others
No phase
19 of 29
2 open now
Registered
28th of 29
by date

Among the 29 studies in Stroke by Tan Tock Seng Hospital, this one is the 2nd largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, and was the 28th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 29 studies in Stroke by Tan Tock Seng Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stroke by Tan Tock Seng Hospital, or all of them as a file.
02

Study summary

This will be a randomized, blinded, sham-controlled trial. The medical device used, Soterix Medical 1x1 tDCS stimulator, is capable of delivering either real or sham tDCS and has been used in many randomised controlled trials in stroke patients.

50 patients with subacute stroke and severe upper limb weakness within 8 weeks of stroke on transfer to TTSH stroke rehab wards will be recruited over a period of 10 months. Recruited patients will be randomized into the intervention and control arms in a 1:1 ratio.

Read the detailed description

The primary objective is to determine the clinical efficacy, technical feasibility and safety of anodal tDCS therapy to the unaffected hemisphere in hospitalized subacute stroke patients with severe arm weakness.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • stroke
  • tdcs
  • upper limb
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First ever unilateral ischaemic or haemorrhagic stroke, as documented by CT or MRI scans
  • Age 21-80 years, both males and females
  • Within 8 weeks of stroke onset
  • Severe weakness of one upper limb, defined by a Shoulder Abduction and Finger Extension (SAFE) score \< 5 (Medical Research Council grading)
  • Provision of by patient or a legal guardian in accordance with the local ethics committee guidelines and the Declaration of Helsinki

Exclusion criteria

Exclusion Criteria:

  • Bilateral hemispheric or cerebellar strokes
  • Pre-existing arm pathology (e.g. contracture, severe pain, etc.) on the affected side
  • Presence of brain implants, and previous insertion of external ventricular drains.
  • Metallic implants at the level of the neck, mouth cavity and below are permitted (e.g. Cardiac stents, dental implants, pacemakers and other metallic objects)
  • A history of spontaneous seizures, epilepsy, brain tumour, and cranial surgery
  • Severe cognitive impairment (MOCA Score \<10) that would hinder sufficient understanding of the instructions
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Anodal tDCS

    Anodal tDCS to contralateral dorsal premotor cortex (dPMc)

    Device: Anodal tDCS

  • Sham comparator
    Sham tDCS

    Sham tDCS to contralateral dorsal premotor cortex (dPMc)

    Device: Sham tDCS

Interventions

  • DeviceAnodal tDCS

    This anodal tDCS is applied over the contralateral dorsal premotor cortex (instead of the ipsilateral motor cortex in previous studies).

    Also known as: tDCS

  • DeviceSham tDCS

    Sham tDCS is applied

    Also known as: tdcs

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Upper Limb

    Fugl-Meyer Upper Limb

    Time frame: At baseline (Day 0) At end of 10 tDCS sessions (Day 10) At 3 months after the 10th tDCS session (Month 3)

Secondary outcomes

  1. Streamlined Wolf Motor Function Test (sWMFT)

    Streamlined Wolf Motor Function Test (sWMFT)

    Time frame: At baseline (Day 0) At end of 10 tDCS sessions (Day 10) At 3 months after the 10th tDCS session (Month 3)

  2. Functional Independence Measure (FIM)

    Functional Independence Measure (FIM) is a widely used objective assessment tool in rehabilitation to evaluate a patient's functional abilities and track their progress. It is a 18-item, 7-level scale, with higher scores indicating greater independence. The total FIM score ranges from 18 to 126.

    Time frame: At baseline (Day 0) At end of 10 tDCS sessions (Day 10)

  3. EQ5D-5L

    The EurolQol 5-Dimension 5-Level (EQ5D-5L) is a widely-used, non-disease specific questionnaire designed to assess a patient's health related quality of life. It serves as a patient-reported outcome instrument, capturing the patient's own perspective on their health. It consists of a descriptive system of five questions (each scored from Level 1 to 5, with a higher score indicating more severe problems) and a visual analogue scale (VAS) for overall health assessment. A higher VAS (from 0 to 100) would indicate a better quality of life.

    Time frame: At baseline (Day 0) and at 3 months after the 10th tDCS session (Month 3)

  4. Rate of Adverse Events from tDCS

    An adverse events questionnaire is administered immediately after each tDCS session. As such, each participant would fill up 10 adverse effects questionnaires after a total of 10 tDCS sessions. The rate of adverse events from tDCS would be computed from the number of adverse events divided by the total number of tDCS sessions.

    Time frame: Immediately after each tDCS session (total 10 sessions of tDCS)

07

Study locations

1 of 1 sites recruiting
  • Tan Tock Seng Hospital - Integrated Care Hub
    Singapore, Singapore 307382, Singapore
    Recruiting
    • WAI PING ALFRED SENG, MBBS, MRCP · Contactalfred_seng@ttsh.com.sg · +65 68894580
    • WAI PING ALFRED SENG · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — To protect the privacy of participants. Preparing IPD for sharing can also be time-consuming and resource-intensive.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2026, 12 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 12 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Sep 3, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Sep 15, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07151729
Collaborators
Ng Teng Fong Healthcare Innovation Programme
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Sep 15, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 3, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion